Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.8852W HIGH $3.12
Volume
743.38 K
Value Traded
11.48 M
Short % Float
13.59%
+24.65%Week
+33.33%1 Month
+98.52%3 Month
+52.27%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
20.71 M
EPS (TTM)
-0.33
P/E Ratio
-
Ent. Value
19.09 M
Total Shares
7.73 M
Float Shares
380.00 K
Insiders
95.14%
Institutions
1.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
HWH Catalyst Timeline
Dated clinical, regulatory and corporate events for HWH International Inc. Common Stock
Past FDA Catalysts and PDUFA Decisions
How HWH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every HWH program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chan Heng Fai AmbroseDirector, Officer (Chief Executive Officer), 10% Owner | Buy | 250,000 5,261,719 held | $2.00 | 06/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in HWH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in HWH for Q2 2026. | ||||
HWH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How HWH ranks across every disease it competes in
Competitive Position is a premium feature
See how HWH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialHWH News
About HWH International Inc. Common Stock
Headquarters4800 MONTGOMERY LANE, SUITE 210, BETHESDA, MD, 20814
BIOPHARMAWATCH ELITE PLUS
Trade the next HWH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime